# QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

> **NCT01106248** · PHASE1 · COMPLETED · sponsor: **Eisai Limited** · enrollment: 26 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Eribulin Mesylate

## Key facts

- **NCT ID:** NCT01106248
- **Lead sponsor:** Eisai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-09
- **Final completion:** —
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106248, "QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01106248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*